Fate Therapeutics Inc. (NASDAQ:FATE) finished Friday with an addition of $0.07 to close at $2.63, an upside of 2.73 percent. An average of 1,720,980 shares of common stock have been traded in the last five days. There was a fall of -$0.15 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 2,025,240 shares traded, while the 50-day average volume stands at 2,127,386.
FATE stock has decreased by -35.85% in the last month. The company shares reached their 1-month lowest point of $2.49 on 08/25/23. With the stock rallying to its 52-week high on 01/05/23, shares of the company touched a low of $2.56 and a high of $31.58 in 52 weeks. It has reached a new high 3 times so far this year and lost -73.93% or -$7.46 in price. In spite of this, the price is down -91.67% from the 52-week high.
Insider Transactions
FATE stock investors should be aware that Fate Therapeutics Inc. (FATE) stock had its last reported insider trading activity 8 days ago on Aug 18. In this transaction, the insider spent $13,210. Director, Xu Yuan, disposed of 632 shares at a price of $3.71 on Aug 04. The insider now owns more than $2,345 worth of shares. Prior to that, Chief Financial Officer Dulac Edward J III went on to Sale 5,182 shares at $4.83 each on Jul 05. An amount of $25,029 was transacted.
Valuation Metrics
Fate Therapeutics Inc. (FATE) stock’s beta is 1.50. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 2.17, the price-to-book (PB) ratio at 0.59.
Financial Health
The quick ratio of Fate Therapeutics Inc. for the three months ended June 29 was 8.80, and the current ratio was 8.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Fate Therapeutics Inc.’s EBITDA margin for the year ending June 29 is -305.95%. Its gross profit as reported stood at $404.69 million compared to revenue of $96.3 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Fate Therapeutics Inc.’s return on assets was -31.70%.
Earnings Surprise
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$52.76 million in the quarter, while revenues of -$18.88 million were shrunk -44.26%. The analyst consensus anticipated Fate Therapeutics Inc.’s latest quarter earnings to come in at -$0.59 per share, but it turned out to be -$0.54, a 8.50% surprise. For the quarter, EBITDA amounted to -$61.04 million. Shareholders own equity worth $98.56 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Fate Therapeutics Inc. (FATE) price momentum. RSI 9-day as of the close on 25 August was 18.55%, suggesting the stock is oversold, with historical volatility in this time frame at 14.09%.
As of today, FATE’s price is $2.66 -5.40% or -$0.15 from its 5-day moving average. FATE is currently trading -37.53% lower than its 20-day SMA and -54.73% lower than its 100-day SMA. However, the stock’s current price level is -51.57% below the SMA50 and -86.64% below the SMA200.
The stochastic %K and %D were 7.82% and 6.68%, respectively, and the average true range (ATR) was 0.18. With the 14-day stochastic at 10.59% and the average true range at 0.20, the RSI (14) stands at 19.43%. The stock has reached -0.10 on the 9-day MACD Oscillator while the 14-day reading was at -0.29.
Analyst Ratings
The consensus rating for Fate Therapeutics Inc. (FATE) among analysts is Hold. According to current brokerage recommendations, 1 brokerage firm advise that investors sell FATE, while 14 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 5 others rate it as a “buy”.
What is FATE’s price target for the next 12 months?
Analysts predict a range of price targets between $4.00 and $16.00, with a median target of $6.00. Taking a look at these predictions, the average price target given by analysts for Fate Therapeutics Inc. (FATE) stock is $7.19.
